bifunctional tgf-beta antagonist/il-15 protein complex hcw9218
Generic: Bifunctional TGF-beta Antagonist/IL-15 Protein Complex HCW9218
bifunctional tgf-beta antagonist/il-15 protein complex hcw9218: 1 clinical trial tracked.
bifunctional tgf-beta antagonist/il-15 protein complex hcw9218 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bifunctional tgf-beta antagonist/il-15 protein complex hcw9218, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer
Primary endpoint: Occurrence of Adverse Events and Treatment-Related Adverse Events
Interventionalopen21 enrolledStarted 2022-10Completion 2025-025 sites · United StatesImmunityBio, Inc.